Cargando…
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
The prodrug capecitabine (Xeloda) has been an important drug for treatment for gastrointestinal cancer (GI-cancer). This study explores the efficacy of continuous metronomic Xeloda, as well as tolerability and best response during treatment. Patients (n = 35) with stage IV GI-cancer were included in...
Autores principales: | Miger, Jasmine, Holmqvist, Annika, Sun, Xiao-Feng, Albertsson, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933740/ https://www.ncbi.nlm.nih.gov/pubmed/24510794 http://dx.doi.org/10.1007/s12032-014-0870-2 |
Ejemplares similares
-
Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018) -
Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
por: Noorali, Sima, et al.
Publicado: (2021) -
A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
por: Vasey, P A, et al.
Publicado: (2003) -
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008) -
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
por: Delord, J P, et al.
Publicado: (2005)